In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.
The company said its product revenues for the year rose 101 percent while its services revenues rose 7 percent.
The offer put a value of 181 pence per share on Horizon's stock, representing a premium of approximately 26 percent to Horizon's closing share price on May 1.
The company has developed an NGS-based discovery approach that allows it to more thoroughly explore the antibody repertoire produced by immunized animals.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
The researchers are currently incorporating new technology that they say will shave an additional two to three weeks off their antibody generation workflow.
It will purchase AxioMx for $20 million followed by additional performance-based payments totaling up to $25 million to be paid over the next five years.
The deal gives Abcam exclusive access to more than 1,800 human diploid and haploid cell lines from Horizon's X-MAN collection.
Abcam was encouraged to buy Firefly BioWorks by its customers, who are more frequently complementing their protein analysis work with miRNA studies.
The all-cash deal gives Abcam access to Firefly's multiplex assay biomarker-detection platform.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.